PTEN/MMAC1/TEP1 involvement in primary prostate cancers
- PMID: 9671408
- DOI: 10.1038/sj.onc.1202081
PTEN/MMAC1/TEP1 involvement in primary prostate cancers
Abstract
The PTEN/MMAC1/TEP1 gene, located at 10q23.3, is a tumor suppressor gene responsible for the familial cancer syndromes Cowden disease and Bannayan-Zonana syndrome, and is commonly somatically mutated in several types of cancers. Mutations of the PTEN gene have been found in prostate cancer cell lines and LOH at 10q22-24 in prostate tumors have also been described with a high frequency. To determine the role of this gene in prostate tumorigenesis, we therefore analysed 22 primary tumors for loss of heterozygosity (LOH) within the 10q22-23 region such that tumors hemizygous at those loci may be examined for somatic PTEN mutations. Losses of heterozygosity of at least one locus was found in 12 (55%) of the 22 tumors DNAs. Among these, six tumors exhibited allele loss in the interval between D10S1765 and D10S541 wherein lies the PTEN gene. We searched the entire coding region of PTEN for somatic mutations in these six tumors. One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in one tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.
Similar articles
-
Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers: evidence for inactivation of both alleles.Jpn J Cancer Res. 1998 Aug;89(8):842-8. doi: 10.1111/j.1349-7006.1998.tb00638.x. Jpn J Cancer Res. 1998. PMID: 9765621 Free PMC article.
-
Analysis of PTEN and the 10q23 region in primary prostate carcinomas.Oncogene. 1998 Apr 2;16(13):1743-8. doi: 10.1038/sj.onc.1200205. Oncogene. 1998. PMID: 9582022
-
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.Cancer Res. 1997 Dec 1;57(23):5221-5. Cancer Res. 1997. PMID: 9393738
-
PTEN and myotubularin: novel phosphoinositide phosphatases.Annu Rev Biochem. 2001;70:247-79. doi: 10.1146/annurev.biochem.70.1.247. Annu Rev Biochem. 2001. PMID: 11395408 Review.
-
Genetics of Cowden syndrome: through the looking glass of oncology.Int J Oncol. 1998 Mar;12(3):701-10. doi: 10.3892/ijo.12.3.701. Int J Oncol. 1998. PMID: 9472113 Review.
Cited by
-
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.Oral Oncol. 2015 Apr;51(4):383-8. doi: 10.1016/j.oraloncology.2014.12.013. Epub 2015 Jan 13. Oral Oncol. 2015. PMID: 25593016 Free PMC article. Clinical Trial.
-
Association between PTEN Gene IVS4 polymorphism and risk of cancer: a meta-analysis.PLoS One. 2014 Jun 5;9(6):e98851. doi: 10.1371/journal.pone.0098851. eCollection 2014. PLoS One. 2014. PMID: 24901890 Free PMC article.
-
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11563-8. doi: 10.1073/pnas.201167798. Epub 2001 Sep 11. Proc Natl Acad Sci U S A. 2001. PMID: 11553783 Free PMC article.
-
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.Br J Cancer. 2013 Sep 3;109(5):1085-92. doi: 10.1038/bjc.2013.474. Epub 2013 Aug 13. Br J Cancer. 2013. PMID: 23942080 Free PMC article. Clinical Trial.
-
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.Am J Pathol. 1999 Oct;155(4):1271-9. doi: 10.1016/S0002-9440(10)65229-7. Am J Pathol. 1999. PMID: 10514409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials